Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 455
6
Diseases
21
Unique genes
0.217
Avg. similarity score
Dandy-walker syndrome
Most-connected disease (5 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Dandy-walker syndrome
Joubert syndrome 21
Joubert syndrome with jeune asphyxiating thoracic dystrophy
Joubert syndrome with or without jeune asphyxiating thoracic dystrophy
Congenital cerebral hernia
Joubert syndrome 30
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Dandy-walker syndrome | 5 | 5 | 21 |
| Joubert syndrome 21 | 3 | 3 | 1 |
| Joubert syndrome with jeune asphyxiating thoracic dystrophy | 3 | 3 | 1 |
| Joubert syndrome with or without jeune asphyxiating thoracic dystrophy | 3 | 3 | 1 |
| Congenital cerebral hernia | 1 | 1 | 1 |
| Joubert syndrome 30 | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CSPP1 | 4 / 6 | Dandy-walker syndrome, Joubert syndrome 21, Joubert syndrome with jeune asphyxiating thoracic dystrophy, Joubert syndrome with or without jeune asphyxiating thoracic dystrophy |
| ARMC9 | 2 / 6 | Dandy-walker syndrome, Joubert syndrome 30 |
| PIBF1 | 2 / 6 | Congenital cerebral hernia, Dandy-walker syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Focal adhesion | KEGG | 3 / 203 | 8.5× | 5.06e-3 | 3.67e-2 ✓ sig. |
| Lysine degradation | KEGG | 2 / 63 | 18.2× | 5.33e-3 | 3.81e-2 ✓ sig. |
| Long-term potentiation | KEGG | 2 / 67 | 17.1× | 6.01e-3 | 4.11e-2 ✓ sig. |
| PKMTs methylate histone lysines | Reactome | 2 / 71 | 16.1× | 6.73e-3 | 4.43e-2 ✓ sig. |
| Melanoma | KEGG | 2 / 73 | 15.7× | 7.10e-3 | 4.59e-2 ✓ sig. |
| Regulation of actin cytoskeleton | KEGG | 3 / 232 | 7.4× | 7.32e-3 | 4.67e-2 ✓ sig. |
| Glioma | KEGG | 2 / 76 | 15.1× | 7.68e-3 | 4.82e-2 ✓ sig. |
| EGFR tyrosine kinase inhibitor resistance | KEGG | 2 / 80 | 14.3× | 8.48e-3 | 5.13e-2 |
| Regulation of PLK1 Activity at G2/M Transition | Reactome | 2 / 88 | 13.0× | 1.02e-2 | 5.75e-2 |
| Gap junction | KEGG | 2 / 89 | 12.9× | 1.04e-2 | 5.84e-2 |
| Negative feedback regulation of MAPK pathway | Reactome | 1 / 6 | 95.3× | 1.04e-2 | 5.84e-2 |
| Synthesis of diphthamide-EEF2 | Reactome | 1 / 7 | 81.7× | 1.22e-2 | 6.41e-2 |
| Prostate cancer | KEGG | 2 / 98 | 11.7× | 1.25e-2 | 6.52e-2 |
| Frs2-mediated activation | Reactome | 1 / 12 | 47.7× | 2.08e-2 | 8.77e-2 |
| Vascular smooth muscle contraction | KEGG | 2 / 134 | 8.5× | 2.26e-2 | 9.18e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| cell migration involved in coronary angiogenesis | GO:0060981 | 1 / 1 | 890× | 1.12e-3 | 1.55e-2 ✓ sig. |
| metanephric glomerular mesangial cell proliferation involved in metanephros development | GO:0072262 | 1 / 1 | 890× | 1.12e-3 | 1.55e-2 ✓ sig. |
| glomerular epithelium development | GO:0072010 | 1 / 1 | 890× | 1.12e-3 | 1.55e-2 ✓ sig. |
| positive regulation of hematopoietic stem cell differentiation | GO:1902038 | 1 / 1 | 890× | 1.12e-3 | 1.55e-2 ✓ sig. |
| beta-catenin-TCF complex assembly | GO:1904837 | 1 / 1 | 890× | 1.12e-3 | 1.55e-2 ✓ sig. |
| visual learning | GO:0008542 | 2 / 54 | 33.0× | 1.66e-3 | 1.93e-2 ✓ sig. |
| pattern specification process | GO:0007389 | 2 / 60 | 29.7× | 2.05e-3 | 2.15e-2 ✓ sig. |
| cell migration involved in vasculogenesis | GO:0035441 | 1 / 2 | 445× | 2.25e-3 | 2.24e-2 ✓ sig. |
| smooth muscle cell chemotaxis | GO:0071670 | 1 / 2 | 445× | 2.25e-3 | 2.24e-2 ✓ sig. |
| apoptotic process involved in outflow tract morphogenesis | GO:0003275 | 1 / 2 | 445× | 2.25e-3 | 2.24e-2 ✓ sig. |
| negative regulation of apoptotic process involved in outflow tract morphogenesis | GO:1902257 | 1 / 2 | 445× | 2.25e-3 | 2.24e-2 ✓ sig. |
| maintenance of cell number | GO:0098727 | 1 / 2 | 445× | 2.25e-3 | 2.24e-2 ✓ sig. |
| cilium assembly | GO:0060271 | 3 / 237 | 11.3× | 2.26e-3 | 2.26e-2 ✓ sig. |
| hippocampus development | GO:0021766 | 2 / 74 | 24.1× | 3.09e-3 | 2.65e-2 ✓ sig. |
| positive T cell selection | GO:0043368 | 1 / 3 | 297× | 3.37e-3 | 2.76e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Joubert syndrome 21 | Joubert syndrome with or without jeune asphyxiating thoracic dystrophy | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Joubert syndrome 21 | Joubert syndrome with jeune asphyxiating thoracic dystrophy | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Joubert syndrome with jeune asphyxiating thoracic dystrophy | Joubert syndrome with or without jeune asphyxiating thoracic dystrophy | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Congenital cerebral hernia | Dandy-walker syndrome | 0.048 | 1 | 1.29e-3 | 1.89e-3 ✓ sig. |
| Dandy-walker syndrome | Joubert syndrome 21 | 0.048 | 1 | 1.29e-3 | 1.89e-3 ✓ sig. |
| Dandy-walker syndrome | Joubert syndrome 30 | 0.048 | 1 | 1.29e-3 | 1.89e-3 ✓ sig. |
| Dandy-walker syndrome | Joubert syndrome with jeune asphyxiating thoracic dystrophy | 0.048 | 1 | 1.29e-3 | 1.89e-3 ✓ sig. |
| Dandy-walker syndrome | Joubert syndrome with or without jeune asphyxiating thoracic dystrophy | 0.048 | 1 | 1.29e-3 | 1.89e-3 ✓ sig. |